OX2R-004: Phase 1 Wet-Lab — Reference + Stabilised Variant (S1)

Ox2r-004: Phase 1 Wet-lab — Reference + Stabilised Variant (S1)

OX2R

Peptide therapeutics — CNS / ADHD / orexin receptor agonism

OX2R-004-S1 is a stabilised ncAA variant (Ac + D-Arg4 + D-Tyr5) of OX2R-004, designed for ADHD via the orexin pathway and engineered to address the Gate 6 proteolytic-stability flag (predicted serum t1/2 15 to 55 min, cleavage sites 34 to 28). Phase 1 wet-lab tests OX2R-004-S1 against the natural-AA parent OX2R-004 and Orexin-B (native ligand) at Adaptyv (BLI + OX1R counter-screen), with cAMP HTRF at Ginkgo on top binders and plasma-stability LC-MS. Comparative output addresses both the stability and OX1R-selectivity flags from the computational pipeline.

Description

Team

0xda935…da668

Owner

Organisation

BIO Protocol

Experiment Cost

$7,750.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Ox2r-004: Phase 1 Wet-lab — Reference + Stabilised Variant (S1)

OX2R

Peptide therapeutics — CNS / ADHD / orexin receptor agonism

Description

Team

0xda935…da668

Owner

Organisation

BIO Protocol

Experiment Cost

$7,750.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project is entirely computational with no wet-lab experiments conducted. All evidence consists of in-silico predictions including structure-based design, PRODIGY binding energy calculations, ADMET predictions, immunogenicity screening, and exploratory molecular dynamics simulations. The project explicitly states "No wet-lab experiments, binding assays, cell-based assays, animal studies, or any empirical testing has been performed," placing it squarely at TRL 1 (Concept Alone). Planned future experiments (Gate G9) have not yet been initiated.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.85

Overall Assessment

OX2R-004 achieves a final weighted score of 3.85 out of 5.00, reflecting a promising but early-stage TRL 1 project with notable strengths and identifiable risks. The strongest dimension is therapeutic relevance (score 4/5, weighted 2.40): the orexin hypothesis for ADHD is scientifically grounded, the target is clinically validated (albeit for different indications), and the computational pipeline is thorough and well-structured. Intellectual property (score 4/5, weighted 1.00) is also strong due to the novel peptide agonist modality in a landscape dominated by small molecules, though it awaits experimental validation to solidify patentability. Therapeutic optionality (score 3/5, weighted 0.45) is moderate — the orexin system touches multiple CNS disorders, but the candidate's delivery constraints and competitive landscape limit pivot flexibility. Key risks that prevent higher scores include: the G6 proteolytic instability failure (serum t½ ~5 min), the G8b OX1R cross-reactivity concern (near-identical binding pockets), the complete absence of wet-lab validation, and several deferred/pending computational gates (G4, G5). The project demonstrates rigorous computational due diligence and a clear-eyed assessment of its own limitations, with a well-defined experimental validation plan (G9) that could rapidly de-risk or terminate the candidate at modest cost ($500–$1,500). The 3.85 score positions this as an above-average TRL 1 concept that merits advancement to wet-lab validation, contingent on the Boltz-2 co-fold results and initial binding assay outcomes.

Weighted Score

Therapeutic Relevance

The mechanism is scientifically plausible and targets a biologically relevant pathway: orexin system dysfunction in ADHD is supported by evidence that drug-naive ADHD children show decreased orexin-A/B levels. OX2R agonism is a validated biological mechanism (endogenous Orexin-B is a natural OX2R agonist with well-characterized signaling). The therapeutic hypothesis is strengthened by clinical-stage OX2R agonists (TAK-861, ORX750, BP1.15205) validating the target, albeit for narcolepsy rather than ADHD. However, the score is not a 5 because: (1) the ADHD indication for OX2R agonism is novel and unvalidated clinically — all clinical programs target narcolepsy/sleep disorders, so the translational leap to ADHD adds uncertainty; (2) no wet-lab validation has been performed — all evidence is computational; (3) the G6 proteolytic instability failure (serum t½ ~5 min) and G8b OX1R cross-reactivity concern (90-100% pocket conservation) represent significant mechanistic delivery challenges; and (4) key computational gates (G4 binding energy, G5 molecular dynamics) remain pending/deferred, leaving the binding interaction incompletely characterized.

Therapeutic Optionality

Moderate therapeutic optionality. The orexin system is implicated in multiple CNS conditions beyond ADHD, including narcolepsy (where OX2R agonists are already in clinical trials), excessive daytime sleepiness, and potentially depression, anxiety, and cognitive disorders — providing some indication flexibility. The peptide agonist modality could theoretically be adapted to other orexin-related indications. However, optionality is constrained by several factors: (1) the peptide is specifically designed for OX2R orthosteric binding, limiting pivot to fundamentally different targets; (2) the 90-100% OX1R/OX2R pocket conservation means the candidate likely acts as a dual agonist rather than selective OX2R agonist, which could be a liability in some indications but an advantage in others (e.g., narcolepsy); (3) the BBB penetration gap and proteolytic instability limit the concept primarily to intranasal delivery for CNS indications, restricting route-of-administration flexibility; (4) the competitive landscape for narcolepsy (the most obvious alternative indication) is already crowded with small-molecule OX2R agonists in advanced clinical stages.

Intellectual Property

Strong novelty position. The concept is highly differentiated: no peptide OX2R agonists exist in clinical development — all clinical-stage OX2R agonists (TAK-861, ORX750, BP1.15205) are small molecules. OX2R-004 represents a novel modality (peptide agonist) for a validated target, and the specific 18-residue sequence (KGDRYGVAYEHGGAQPFK) is a de novo design, not a truncation of natural Orexin-B. The stabilized variant OX2R-004-S1 with D-amino acid substitutions and N-acetylation adds further composition-of-matter novelty. The intranasal chitosan nanoparticle delivery strategy could support additional formulation IP. The score is not a 5 because: (1) the concept builds on well-known orexin biology and the publicly available PDB 7L1U structure, so the underlying science is in the public domain; (2) prior art risk exists from the extensive orexin peptide literature (natural Orexin-A and Orexin-B sequences and their analogs); (3) without wet-lab validation of binding or function, the IP position is based entirely on computational predictions — a patent application would be strengthened substantially by experimental data; and (4) the competitive small-molecule programs may generate blocking IP around OX2R agonism for specific indications.